propranolol has been researched along with Shoulder Pain in 2 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Shoulder Pain: Unilateral or bilateral pain of the shoulder. It is often caused by physical activities such as work or sports participation, but may also be pathologic in origin.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| George, SZ | 2 |
| Bishop, MD | 1 |
| Wu, SS | 2 |
| Staud, R | 2 |
| Borsa, PA | 2 |
| Wallace, MR | 2 |
| Greenfield, WH | 2 |
| Dai, Y | 1 |
| Fillingim, RB | 2 |
| Mackie, LN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Biopsychosocial Influence on Shoulder Pain: a Randomized, Pre-clinical Trial[NCT02620579] | Phase 2 | 264 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Brief Pain Inventory (BPI) consists of rating pain intensity on an 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain intensity imaginable). BPI will be recorded daily and the recovery criterion used for this study will be a BPI rating of current pain 0/10 and worst pain rating of less than 2/10. The pain duration is number of days from the date of induced pain to date of recovery. The longer the duration means a worse outcome. (NCT02620579)
Timeframe: Daily until recovery criterion met, approximately 5-15 days
| Intervention | days (Median) |
|---|---|
| Personalized Pharmaceutical and Education (C) | 4 |
| Placebo Pharmaceutical, General Education (B) | 4 |
| Placebo Pharmaceutical, Personalized Education (A) | 4 |
| Personalized Pharmaceutical, General Education (D) | 4 |
The Brief Pain Inventory (BPI) which consists of rating pain intensity on an 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain intensity imaginable). Participants will rate their current, best, and worst pain intensity on the BPI. This measure will be recorded daily through study completion, an average of 5 days. The worst pain intensity rating at Day 2 (when participants usually had the Peak Shoulder Pain Intensity) is reported. (NCT02620579)
Timeframe: Day 2 value of the worst pain intensity is reported
| Intervention | score on a scale (Mean) |
|---|---|
| Personalized Pharmaceutical and Education (C) | 2.9 |
| Placebo Pharmaceutical, General Education (B) | 3.2 |
| Placebo Pharmaceutical, Personalized Education (A) | 2.9 |
| Personalized Pharmaceutical, General Education (D) | 3.1 |
The abridged version of the DASH (the QuickDASH) which consists of 11 functional items, with total scores ranging from 0 (not disability) to 100 (complete disability) will be used to assess upper-extremity disability. The primary outcome will be the highest DASH score recorded during the pain intensity recovery period. (NCT02620579)
Timeframe: Daily until recovery criterion met, approximately 5-15 days
| Intervention | score on a scale (Mean) |
|---|---|
| Personalized Pharmaceutical and Education (C) | 8.2 |
| Placebo Pharmaceutical, General Education (B) | 10.5 |
| Placebo Pharmaceutical, Personalized Education (A) | 11.4 |
| Personalized Pharmaceutical, General Education (D) | 9.4 |
The outcome has a range between 0 and 1, the higher scores mean a better outcome. Successful recovery was determined based on meeting the recovery criterion for shoulder pain intensity by at least 6 days. Specifically, recovery (Yes or No) was defined using Brief Pain Inventory (BPI) ratings as a current pain intensity rating of 0/10 and a worst pain intensity rating of less than 2/10. (NCT02620579)
Timeframe: Approximately 6 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Personalized Pharmaceutical and Education (C) | 39 |
| Placebo Pharmaceutical, General Education (B) | 32 |
| Placebo Pharmaceutical, Personalized Education (A) | 32 |
| Personalized Pharmaceutical, General Education (D) | 32 |
2 trials available for propranolol and Shoulder Pain
| Article | Year |
|---|---|
Biopsychosocial influence on shoulder pain: results from a randomized preclinical trial of exercise-induced muscle injury.
Topics: Cohort Studies; Exercise Therapy; Humans; Muscles; Propranolol; Shoulder Pain | 2023 |
Biopsychosocial influence on shoulder pain: Rationale and protocol for a pre-clinical trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Catastrophization; Catechol O-Methyltransferas | 2017 |